Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Pembrolizumab	62
Overall Study	STARTED	Chemotherapy	61
Overall Study	Treated	Pembrolizumab	62
Overall Study	Treated	Chemotherapy	59
Overall Study	Received Second Course	Pembrolizumab	1
Overall Study	Received Second Course	Chemotherapy	0
Overall Study	Discontinued	Pembrolizumab	62
Overall Study	Discontinued	Chemotherapy	61
Overall Study	COMPLETED	Pembrolizumab	0
Overall Study	COMPLETED	Chemotherapy	0
Overall Study	NOT COMPLETED	Pembrolizumab	62
Overall Study	NOT COMPLETED	Chemotherapy	61

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03933449/flow